SAB Biotherapeutics Reports NIH is Discontinuing Phase 3 ACTIV-2 Trial Assessing SAB-185 for Treatment of COVID-19 Due to Declining COVID Hospitalizations NIH is closing enrollment in its ACTIV-2 trial due to low Omicron-related COVID-19 hospitalization and death rates that have made the current study design statistically unworkable SAB-185 had advanced...

SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19 ACTIV-2 Phase 3 trial continuing as placebo-controlled study in Omicron variant COVID participants SIOUX FALLS, S.D., Feb. 25, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (SAB) (Nasdaq: SABS), a...